Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.
Open Access
- 1 December 1988
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 168 (6) , 2183-2191
- https://doi.org/10.1084/jem.168.6.2183
Abstract
Addition of IL-4 (1,000 U/ml) to either high or low concentrations of IL-2 augmented tumor-infiltrating lymphocytes (TIL) growth from human melanoma. Weekly restimulation with irradiated tumor cells in conjunction with IL-4 allowed enhanced growth of TIL. With low-dose IL-2 (10 U/ml) and IL-4, expanded TIL had little cytolytic activity against Daudi or allogeneic tumors. Further, IL-4 augmented the total lytic activity against autologous tumors in most cases. With high-dose IL-2 (1,000 U/ml), IL-4 addition decreased nonspecific killing activity against Daudi or allogeneic melanomas in many cases, and reciprocally augmented cytolytic activity against the autologous melanoma in many cases. This suggests the possible use of IL-4 in cancer therapy, especially in adoptive cellular immunotherapy using TIL or in conjunction with IL-2 administration.This publication has 15 references indexed in Scilit:
- IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.The Journal of Immunology, 1988
- Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4).The Journal of Experimental Medicine, 1987
- Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.The Journal of Experimental Medicine, 1987
- Recombinant interleukin 4 promotes the growth of human T cells.The Journal of Immunology, 1987
- Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trialsJournal of Immunological Methods, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- B-Cell Stimulatory Factor-1/Interleukin 4Annual Review of Immunology, 1987
- Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.The Journal of Immunology, 1987
- Proliferation of T lymphocytes in response to interleukin 2 varies with their state of activation.The Journal of Immunology, 1986
- INVITRO GROWTH OF CYTO-TOXIC HUMAN-LYMPHOCYTES .4. LYSIS OF FRESH AND CULTURED AUTOLOGOUS TUMOR BY HUMAN-LYMPHOCYTES CULTURED IN T-CELL GROWTH-FACTOR1981